BD (NYSE: BDX) Interventional segment leader Rick Byrd plans retirement
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Becton, Dickinson and Company announced that Richard (Rick) Byrd, executive vice president and president of the Interventional segment, has informed the company of his intention to retire after nearly 25 years with BD. He has led the Interventional segment since September 2022 and previously held several other leadership roles.
Byrd will remain in his current position through June, providing time for an orderly transition, and BD intends to name a successor before his retirement date. The company also issued a press release describing his contributions across multiple segments and his role during the COVID-19 pandemic.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Retirement notice date: April 6, 2026
Press release date: April 9, 2026
Tenure at BD: nearly 25 years
+1 more
4 metrics
Retirement notice date
April 6, 2026
Date Rick Byrd informed BD of his intention to retire
Press release date
April 9, 2026
Date BD issued news release about Rick Byrd’s retirement
Tenure at BD
nearly 25 years
Length of time Rick Byrd has been with BD
Role end timeframe
through June
Byrd will remain in his role through June before retiring
Key Terms
Interventional segment, Regulation FD, Inline XBRL, executive vice president
4 terms
Interventional segment financial
"executive vice president and president of the Interventional segment of Becton, Dickinson and Company"
Regulation FD regulatory
"ITEM 7.01. REGULATION FD DISCLOSURE. On April 9, 2026, BD issued a press release"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
Inline XBRL technical
"Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
executive vice president financial
"Byrd is currently executive vice president and president of the Interventional Segment at BD"
An executive vice president is a high-ranking leader within a company who oversees major parts of its operations or strategies. Think of them as senior managers responsible for important areas, similar to a vice principal in a school hierarchy. Their role matters to investors because they help guide the company's success and decision-making at the top level.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 6, 2026
| (Exact Name of Registrant as Specified in Its Charter) | ||||||||||||||
| (State or Other Jurisdiction of Incorporation) | ||||||||||||||
| (Commission File Number) | (IRS Employer Identification No.) | |||||||||||||
| | ||||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
(Registrant’s Telephone Number, Including Area Code) | |||||||||||||||||
N/A | |||||||||||||||||
(Former Name or Former Address, if Changed Since Last Report) | |||||||||||||||||
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
Emerging growth company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | |||||
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On April 6, 2026, Richard E. Byrd, Executive Vice President and President of the Interventional segment of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Mr. Byrd will remain in his role through June. BD intends to name a successor to Mr. Byrd prior to his retirement date.
ITEM 7.01. REGULATION FD DISCLOSURE.
On April 9, 2026, BD issued a press release relating to the matters described above in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01 shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 Press release dated April 9, 2026 which is furnished pursuant to Item 7.01.
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BECTON, DICKINSON AND COMPANY
(Registrant)
| By: | /s/ Stephanie M. Kelly | ||||
| Stephanie M. Kelly | |||||
| Chief Securities and Governance Counsel, Corporate Secretary | |||||
Date: April 9, 2026
NEWS RELEASE 
Rick Byrd to Retire from BD
FRANKLIN LAKES, N.J. (April 9, 2026) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD.
Byrd is currently executive vice president and president of the Interventional Segment at BD, a position he has held since September 2022. During his tenure, Byrd held several leadership roles including worldwide president of Medication Delivery Solutions and worldwide president of Preanalytical Systems. Prior to joining BD in 2004, Byrd held various leadership and engineering positions across the medical device and advanced technology sectors.
“Over his long career, Rick has led his teams to deliver meaningful results for BD – strengthening our portfolio, elevating our operational rigor and advancing BD’s role as a global healthcare leader,” said Tom Polen, chairman, CEO and president of BD. “Rick has driven impact across multiple segments, including expanding BD’s leadership in Vascular Access Management, advancing our ‘One‑Stick Hospital Stay’ vision and leading critical manufacturing scale‑up efforts during the COVID-19 pandemic. We thank Rick for his many contributions to BD and wish him all the best in his retirement.”
Byrd will remain in his role through June. BD intends to name a successor prior to Byrd’s retirement date.
“What has inspired me most throughout my time at BD is the people – the teams who show up every day committed to driving the future of care and improving outcomes for patients everywhere,” Byrd said. “I'm incredibly proud of the meaningful work we’ve accomplished together and am confident that BD will continue to deliver on its purpose of advancing the world of health.”
# # #
About BD
BD is one of the world’s largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
BD is one of the world’s largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts: | |||||
Media | Investors | ||||
Megan Dubrowski Senior Director, Executive Communications Megan.Dubrowski@bd.com | Shawn Bevec SVP, Investor Relations Investor_Relations@bd.com | ||||
FAQ
What executive leadership change did BD (BDX) disclose in this 8-K filing?
BD disclosed that Richard (Rick) Byrd, executive vice president and president of the Interventional segment, plans to retire. He has been with BD nearly 25 years and has held multiple leadership roles, including leading the Interventional segment since September 2022.
When is BD executive Rick Byrd expected to retire from the company?
Rick Byrd informed BD of his intent to retire on April 6, 2026, and will remain in his role through June. This timing allows the company to manage a planned transition and appoint a new leader for the Interventional segment before his retirement date.
What position does Rick Byrd currently hold at BD (BDX)?
Rick Byrd currently serves as executive vice president and president of BD’s Interventional segment. He has held this role since September 2022 and previously led areas such as Medication Delivery Solutions and Preanalytical Systems within the company’s broader medical technology portfolio.
How long has retiring executive Rick Byrd been with BD (BDX)?
Rick Byrd is retiring after nearly 25 years with BD. During this time, he held several leadership positions across multiple segments, helping strengthen the portfolio, expand vascular access leadership, and support critical manufacturing scale-up efforts during the COVID-19 pandemic.
How does BD plan to handle succession for the Interventional segment after Byrd retires?
BD stated that Rick Byrd will remain in his role through June and that it intends to name a successor prior to his retirement. This indicates a planned leadership transition designed to maintain continuity within the Interventional segment’s operations and strategic initiatives.
What additional disclosure did BD (BDX) provide alongside this leadership change?
BD issued a press release on April 9, 2026, discussing Rick Byrd’s retirement and highlighting his contributions, including expanding vascular access leadership and COVID-19 manufacturing efforts. The release was furnished as Exhibit 99.1 under Regulation FD, not filed for liability purposes.